Skin tolerability of transdermal patches

被引:15
|
作者
Wohlrab, Johannes [1 ,2 ]
Kreft, B. [1 ]
Tamke, B. [3 ]
机构
[1] Univ Halle Wittenberg, Dept Dermatol & Venereol, D-06097 Halle, Saale, Germany
[2] Univ Halle Wittenberg, Inst Appl Dermatopharm, D-06097 Halle, Saale, Germany
[3] Univ Halle Wittenberg, Dept Anaesthesiol & Intens Care, D-06097 Halle, Saale, Germany
关键词
drug delivery; intolerance; safety and tolerability; transdermal patch systems; ALOE-VERA GEL; DRUG-DELIVERY; DOUBLE-BLIND; BARBADENSIS MILLER; THERAPEUTIC SYSTEM; PHENOLIC-COMPOUNDS; PHASE-III; EFFICACY; BUPRENORPHINE; STIMULATION;
D O I
10.1517/17425247.2011.574689
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Transdermal patch systems are an effective method of administering active ingredients through the skin, with considerable advantages over other drug delivery routes, for example, maintenance of constant plasma drug levels and avoidance of first-pass metabolism. However, repeated epicutaneous application may be associated with local skin reactions. Areas covered: This review addresses current issues regarding the effective/safe use of transdermal patch systems, and provides a critical analysis of the addition of 'skin-caring' ingredients to patch systems. Effective use of transdermal systems includes choosing an appropriate body area for application, maintaining regular skin care regimens before application and not replacing a patch in the same area (rotation) within 7 days. Another strategy, developed in an attempt to improve the tolerability of transdermal systems, is the addition of assumed 'skin-caring' ingredients (e.g., Aloe Vera) to patch systems. However, at present there is neither proof nor clinical evidence of any benefit. On the contrary, plant-derived ingredients might be associated with allergenic potential. Expert opinion: Transdermal systems are generally well tolerated; physicians must adequately inform patients of the most effective ways to use these formulations for maximum therapeutic benefit, while minimising local adverse events. Skin-caring agents, including Aloe Vera, cannot be recommended until well-controlled clinical trials with standardised extracts are available.
引用
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [41] Transdermal patches: An unseen risk for harm
    Paparella, S
    JOURNAL OF EMERGENCY NURSING, 2005, 31 (03) : 278 - 281
  • [43] TRANSDERMAL NICOTINE PATCHES - HOW EFFECTIVE ARE THEY
    DENELSKY, GY
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1993, 60 (03) : 252 - 253
  • [44] Preparation of Loxoprofen Sodium Transdermal Patches
    Wang, Juxiang
    Zhou, Da
    Sun, Yongqiang
    Chinese Journal of Pharmaceuticals, 2023, 54 (09) : 1354 - 1359
  • [45] Giving partial doses of transdermal patches
    Lee, HA
    Anderson, PO
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (15) : 1759 - 1760
  • [46] Transdermal patches: past, present and future
    Miller, Ken
    THERAPEUTIC DELIVERY, 2015, 6 (06) : 639 - 641
  • [47] RECENT ADVANCES IN DEVELOPMENT OF TRANSDERMAL PATCHES
    Jatav, Vijay S.
    Saggu, Jitendra S.
    Jat, Rakesh K.
    Sharma, Ashish K.
    Singh, Ravindra P.
    PHARMACOPHORE, 2011, 2 (06): : 251 - 261
  • [48] Transdermal hormone therapy: gels and patches
    Samsioe, G
    CLIMACTERIC, 2004, 7 (04) : 347 - 356
  • [49] Transdermal patches: New era in toxicology!
    Lefebvre, L.
    Blais, R.
    CLINICAL TOXICOLOGY, 2007, 45 (06): : 645 - 645
  • [50] Combination of transdermal patches and solid microneedles for improved transdermal delivery of primaquine
    Ananda, Putri Wulandari Resky
    Elim, Diany
    Zaman, Hilman Syamami
    Muslimin, Wahdaniyah
    Tunggeng, Muhamad Gilang Ramadhan
    Permana, Andi Dian
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 609